Stephens lowered the firm's price target on Cytek Biosciences to $4.75 from $5.50 and keeps an Overweight rating on the shares. While revenue was roughly in line and FY26 guidance was reiterated, operating expenses remain elevated and a roughly $6M EBITDA miss caused shares to trade lower in response, the analyst noted, adding that the firm stays Overweight based on valuation and takeout potential.
